Literature DB >> 36074143

[Quality of life of patients with mycosis fungoides and Sézary syndrome].

Manuel Jäger1,2, Deniz Özistanbullu3, Claus-Detlev Klemke4, Sabine Tratzmiller4.   

Abstract

Mycosis fungoides as the most common type and Sézary syndrome as a leukemic variant belong to the rare group of cutaneous T‑cell lymphomas. Both diseases are considered incurable and show a chronic course. Since there is no curative treatment, maintaining quality of life and relief of symptoms should be important elements when treating patients with mycosis fungoides and Sézary syndrome. Pruritus, which is a common and burdensome symptom of cutaneous T‑cell lymphoma, may negatively impact quality of life. Pruritus and quality of life can be assessed with established measurement tools. Consistent recording enables physicians to recognize restrictions in physical and psychosocial aspects of quality of life early so that therapy can be adapted.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Cutaneous T‑cell lymphomas; Palliative care; Patient-reported outcome; Pruritis; Quality of life

Year:  2022        PMID: 36074143     DOI: 10.1007/s00105-022-05049-7

Source DB:  PubMed          Journal:  Dermatologie (Heidelb)        ISSN: 2731-7005


  23 in total

1.  Dermatology life quality index: time to move forward.

Authors:  Tamar Nijsten
Journal:  J Invest Dermatol       Date:  2012-01       Impact factor: 8.551

Review 2.  The Skindex instruments to measure the effects of skin disease on quality of life.

Authors:  Mary-Margaret Chren
Journal:  Dermatol Clin       Date:  2011-12-20       Impact factor: 3.478

3.  Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness.

Authors:  M M Chren; R J Lasek; L M Quinn; E N Mostow; S J Zyzanski
Journal:  J Invest Dermatol       Date:  1996-11       Impact factor: 8.551

4.  Interventions for mycosis fungoides.

Authors:  Arash Valipour; Manuel Jäger; Peggy Wu; Jochen Schmitt; Charles Bunch; Tobias Weberschock
Journal:  Cochrane Database Syst Rev       Date:  2020-07-07

Review 5.  European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.

Authors:  Franz Trautinger; Johanna Eder; Chalid Assaf; Martine Bagot; Antonio Cozzio; Reinhard Dummer; Robert Gniadecki; Claus-Detlev Klemke; Pablo L Ortiz-Romero; Evangelia Papadavid; Nicola Pimpinelli; Pietro Quaglino; Annamari Ranki; Julia Scarisbrick; Rudolf Stadler; Liisa Väkevä; Maarten H Vermeer; Sean Whittaker; Rein Willemze; Robert Knobler
Journal:  Eur J Cancer       Date:  2017-03-31       Impact factor: 9.162

6.  Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma.

Authors:  Marie-France Demierre; Amy Tien; Donald Miller
Journal:  Arch Dermatol       Date:  2005-03

7.  Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma.

Authors:  Abigail Wright; Aruni Wijeratne; Tracy Hung; Wei Gao; Sean Whittaker; Steven Morris; Julia Scarisbrick; Teresa Beynon
Journal:  J Pain Symptom Manage       Date:  2012-08-20       Impact factor: 3.612

8.  Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.

Authors:  P Quaglino; H M Prince; R Cowan; M Vermeer; E Papadavid; M Bagot; O Servitjie; E Berti; E Guenova; R Stadler; C Querfeld; A M Busschots; E Hodak; A Patsatsi; J Sanches; M Maule; J Yoo; M Kevin; P Fava; S Ribero; L Zocchi; M Rubatto; M T Fierro; U Wehkamp; M Marshalko; C Mitteldorf; O Akilov; P Ortiz-Romero; T Estrach; L Vakeva; P A Enz; M Wobser; M Bayne; C Jonak; M Rubeta; A Forbes; A Bates; M Battistella; R Amel-Kashipaz; B Vydianath; A Combalia; E Georgiou; E Hauben; E K Hong; M Jost; R Knobler; I Amitay-Laish; D Miyashiro; J Cury-Martins; X Martinez; C Muniesa; H Prag-Naveh; A Stratigos; V Nikolaou; K Quint; C Ram-Wolff; K Rieger; R Stranzenbach; Á Szepesi; S Alberti-Violetti; E Felicity; L Cerroni; W Kempf; S Whittaker; R Willemze; Y Kim; J J Scarisbrick
Journal:  Br J Dermatol       Date:  2021-02-18       Impact factor: 9.302

Review 9.  Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature.

Authors:  R Ottevanger; S van Beugen; A W M Evers; R Willemze; M H Vermeer; K D Quint
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-08-14       Impact factor: 9.228

10.  Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma.

Authors:  T Illidge; C Chan; N Counsell; S Morris; J Scarisbrick; D Gilson; B Popova; P Patrick; P Smith; S Whittaker; R Cowan
Journal:  Br J Cancer       Date:  2013-10-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.